ES2869172T3 - Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro - Google Patents
Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro Download PDFInfo
- Publication number
- ES2869172T3 ES2869172T3 ES19177963T ES19177963T ES2869172T3 ES 2869172 T3 ES2869172 T3 ES 2869172T3 ES 19177963 T ES19177963 T ES 19177963T ES 19177963 T ES19177963 T ES 19177963T ES 2869172 T3 ES2869172 T3 ES 2869172T3
- Authority
- ES
- Spain
- Prior art keywords
- group
- independently selected
- ring
- heteroatoms
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Un compuesto que tiene la fórmula: **(Ver fórmula)** en donde R1 es un anillo heteroarilo que tiene de 5 a 6 miembros en el anillo y de 1 a 4 heteroátomos seleccionado cada uno independientemente entre el grupo que consiste en N, O y S, opcionalmente sustituido con de 1 a 4 grupos seleccionado cada uno independientemente entre R1a; cada R1a se selecciona independientemente entre el grupo que consiste en hidrógeno, alquilo C1-6, halógeno, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, N-óxido y cicloalquilo C3-8; el anillo J se selecciona entre el grupo que consiste en un anillo arilo y un anillo heteroarilo que tiene de 5 a 6 miembros en el anillo y de 1 a 4 heteroátomos seleccionados cada uno de ellos independientemente entre el grupo que consiste en N, O y S; cada R2 se selecciona independientemente entre el grupo que consiste en hidrógeno, alquilo C1-6, halógeno, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, alquil C1-6-alcoxi C1-6, -CN, -OH, -NR2aR2b, -C(O)R2a, -C(O)OR2a, - C(O)NR2aR2b, -SR2a, -S(O)R2a, -S(O)2R2a, cicloalquilo C3-8 y heterocicloalquilo C3-8 que tiene de 1 a 3 heteroátomos seleccionados cada uno de ellos independientemente entre el grupo que consiste en N, O y S; como alternativa, dos grupos R2 en átomos adyacentes en el anillo se combinan para formar un anillo heterocicloalquilo que tiene de 5 a 6 miembros en el anillo y de 1 a 3 heteroátomos seleccionados cada uno de ellos independientemente entre el grupo que consiste en N, O y S, en donde el anillo heterocicloalquilo está opcionalmente sustituido con de 1 a 3 grupos R2c y cada uno de R2a, R2b y R2c se selecciona independientemente entre el grupo que consiste en hidrógeno y alquilo C1-6 o sales e isómeros de los mismos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361908333P | 2013-11-25 | 2013-11-25 | |
| US201461985035P | 2014-04-28 | 2014-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2869172T3 true ES2869172T3 (es) | 2021-10-25 |
Family
ID=53180165
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14863514T Active ES2743620T3 (es) | 2013-11-25 | 2014-11-21 | Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro |
| ES19177963T Active ES2869172T3 (es) | 2013-11-25 | 2014-11-21 | Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro |
| ES21158231T Active ES2943542T3 (es) | 2013-11-25 | 2014-11-21 | Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14863514T Active ES2743620T3 (es) | 2013-11-25 | 2014-11-21 | Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES21158231T Active ES2943542T3 (es) | 2013-11-25 | 2014-11-21 | Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro |
Country Status (20)
| Country | Link |
|---|---|
| US (8) | US10047082B2 (es) |
| EP (4) | EP3848027B1 (es) |
| JP (6) | JP6516743B2 (es) |
| KR (1) | KR102352737B1 (es) |
| CN (2) | CN109761976B (es) |
| AU (1) | AU2014352915B2 (es) |
| BR (1) | BR112016011826B1 (es) |
| CA (1) | CA2931302C (es) |
| DK (2) | DK3074011T3 (es) |
| ES (3) | ES2743620T3 (es) |
| FI (1) | FI3848027T3 (es) |
| IL (1) | IL245848B (es) |
| MX (1) | MX368167B (es) |
| MY (1) | MY180141A (es) |
| PH (1) | PH12016500968B1 (es) |
| PL (3) | PL3848027T3 (es) |
| PT (2) | PT3074011T (es) |
| RU (1) | RU2674983C1 (es) |
| WO (1) | WO2015077530A1 (es) |
| ZA (1) | ZA201604026B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12226412B2 (en) | 2012-05-25 | 2025-02-18 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| PT3074011T (pt) | 2013-11-25 | 2019-09-17 | Corcept Therapeutics Inc | Moduladores de receptores de glicocorticoides de azadecalina fundidas com octa-hidro |
| KR102495223B1 (ko) | 2015-03-30 | 2023-02-01 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 부신기능부전을 치료하기 위한 글루코코르티코이드와 조합된 글루코코르티코이드 수용체 길항제의 용도 |
| AU2017228329B2 (en) * | 2016-03-01 | 2021-03-11 | Corcept Therapeutics, Inc. | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors |
| CN106478464B (zh) * | 2016-08-30 | 2018-06-05 | 黄河三角洲京博化工研究院有限公司 | 一种2-氟-6-三氟甲基苯磺酰氯的制备方法 |
| US9943505B2 (en) * | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
| CN110475558A (zh) | 2017-03-09 | 2019-11-19 | 科赛普特治疗学股份有限公司 | 糖皮质激素受体调节剂在儿茶酚胺分泌型肿瘤治疗中的应用 |
| RU2019129299A (ru) * | 2017-03-31 | 2021-04-30 | Корсепт Терапьютикс, Инк. | Модуляторы глюкокортикоидного рецептора для лечения рака шейки матки |
| WO2018209142A2 (en) * | 2017-05-10 | 2018-11-15 | Corcept Therapeutics, Inc. | Octahydro azadecalin formulations |
| AU2018289307B2 (en) * | 2017-06-20 | 2024-02-01 | Corcept Therapeutics, Inc. | Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators |
| CN112261937B (zh) * | 2018-04-10 | 2023-11-14 | 杜克大学 | 乳腺癌的拉索昔芬治疗 |
| CN112004803B (zh) * | 2018-04-23 | 2023-11-03 | 科赛普特治疗公司 | 区域选择的n-烷基三唑的制备方法 |
| TWI811400B (zh) * | 2018-07-20 | 2023-08-11 | 德商歌林達有限公司 | 經進一步取代之三唑并喹噁啉衍生物 |
| IL263184A (en) | 2018-11-21 | 2020-05-31 | Yarden Yosef | Method of treating cancer and compositions for same |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| US11389432B2 (en) | 2018-12-19 | 2022-07-19 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| EP3897589A4 (en) | 2018-12-19 | 2022-10-12 | Corcept Therapeutics Incorporated | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound |
| AU2020226863B2 (en) | 2019-02-22 | 2023-04-06 | Corcept Therapeutics Incorporated | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
| EP4045045A4 (en) | 2019-10-16 | 2023-11-22 | Corcept Therapeutics Incorporated | METHOD FOR NORMALIZING THE RATIO BETWEEN NEUTROPHILS AND LYMPHOCYTES IN CANCER PATIENTS USING A SELECTIVE GLUCOCORTICOID RECEPTOR ANTAGONIST |
| JP7569492B2 (ja) | 2019-12-11 | 2024-10-18 | コーセプト セラピューティクス， インコーポレイテッド | 抗精神病薬誘発性体重増加のミリコリラントによる治療方法 |
| US20230358768A1 (en) | 2019-12-21 | 2023-11-09 | Corcept Therapeutics Incorporated | Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome |
| CN115361952A (zh) | 2020-01-29 | 2022-11-18 | 科赛普特治疗学股份有限公司 | 用选择性糖皮质激素受体调节剂(sgrm)和抗体检查点抑制剂治疗肾上腺皮质癌 |
| CA3187566A1 (en) | 2020-06-22 | 2021-12-30 | Corcept Therapeutics Incorporated | Quaternary indazole glucocorticoid receptor antagonists |
| WO2022134033A1 (en) * | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| TW202246260A (zh) * | 2021-02-03 | 2022-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合的氮雜三環類衍生物、其製備方法及其在醫藥上的應用 |
| JP2025500318A (ja) | 2021-12-21 | 2025-01-09 | コーセプト セラピューティクス， インコーポレイテッド | ピペラジンインダゾールグルココルチコイド受容体拮抗薬 |
| US12098141B2 (en) | 2021-12-21 | 2024-09-24 | Corcept Therapeutics Incorporated | Bicyclic indazole glucocorticoid receptor antagonists |
| WO2024173745A1 (en) * | 2023-02-17 | 2024-08-22 | Corcept Therapeutics Incorporated | Methods and compositions for treating huntington's disease and its symptoms |
| US20240390341A1 (en) * | 2023-05-22 | 2024-11-28 | Corcept Therapeutics Incorporated | Methods for treating adrenal gland tumors |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS322220B1 (es) | 1954-11-30 | 1957-04-11 | ||
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| CA1270488A (en) | 1983-09-26 | 1990-06-19 | John M. Schaus | Pyrazole-ring alkylated pyrazoloquinolines and intermediates |
| GB8828669D0 (en) * | 1988-12-08 | 1989-01-11 | Lilly Industries Ltd | Organic compounds |
| JP3160941B2 (ja) | 1991-06-17 | 2001-04-25 | 東レ株式会社 | カルバゾール誘導体および免疫抑制剤 |
| FR2697252B1 (fr) | 1992-10-28 | 1994-12-09 | Fournier Ind & Sante | Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique. |
| US5731322A (en) | 1993-08-06 | 1998-03-24 | Smithkline Beecham S.P.A. | Octahydro-1H-pyrrolo 3,2-g!and 2,3-g!isoquinoline derivatives |
| CA2683097A1 (en) | 1998-03-10 | 1999-09-16 | Research Triangle Institute | Novel opiate compounds, methods of making and methods of use |
| GB9911053D0 (en) | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
| EP1333842B1 (en) * | 2000-11-02 | 2006-08-30 | Akzo Nobel N.V. | Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders |
| AU2002355929A1 (en) | 2001-07-17 | 2003-03-03 | Smithkline Beecham Corporation | Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same |
| CN1853722A (zh) * | 2001-07-23 | 2006-11-01 | 科塞普特治疗公司 | 预防由抗精神病药物引起的体重增加的方法 |
| US6679935B2 (en) * | 2001-08-14 | 2004-01-20 | Apex Advanced Technologies, Llc | Lubricant system for use in powdered metals |
| AU2003214879B2 (en) | 2002-01-22 | 2008-02-07 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| EP1660081A1 (en) | 2003-09-03 | 2006-05-31 | Wyeth | Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and pharmaceutical compositions containing the same |
| AU2005206497B2 (en) | 2004-01-09 | 2011-02-10 | Corcept Therapeutics, Inc. | Azadecalin glucocorticoid receptor modulators |
| NZ550362A (en) | 2004-03-09 | 2010-06-25 | Corcept Therapeutics Inc | Fused ring azadecalin glucocorticoid receptor modulators |
| PT1928840E (pt) * | 2005-04-05 | 2011-10-03 | Hoffmann La Roche | 1h-pirazole-4-carboxamidas, a sua preparação e a sua utilização a título de inibidores de 11-betahidroxiesteróide desidrogenase |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| EP2209780B1 (en) * | 2007-11-01 | 2014-01-01 | Bristol-Myers Squibb Company | Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and/or nf- kappa b activity and use thereof |
| WO2009100171A1 (en) * | 2008-02-07 | 2009-08-13 | Bristol-Myers Squibb Company | Fused heteroaryl modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof |
| US8461172B2 (en) | 2009-05-12 | 2013-06-11 | Corcept Therapeutics, Inc. | Solid forms and process for preparing |
| US8710035B2 (en) * | 2010-03-24 | 2014-04-29 | The University Of Chicago | Methods and compositions related to glucocorticoid receptor antagonists and breast cancer |
| SG187909A1 (en) | 2010-08-27 | 2013-03-28 | Corcept Therapeutics Inc | Pyridyl-amine fused azadecalin modulators |
| AU2012204232A1 (en) | 2011-01-07 | 2013-06-27 | Corcept Therapeutics, Inc. | Combination steroid and glucocorticoid receptor antagonist therapy |
| US20130225633A1 (en) | 2012-02-27 | 2013-08-29 | Corcept Therapeutics, Inc. | Phenyl heterocycloalkyl glucocorticoid receptor modulators |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| EP4434584A3 (en) | 2012-05-25 | 2024-11-20 | Corcept Therapeutics Incorporated | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| PT3074011T (pt) | 2013-11-25 | 2019-09-17 | Corcept Therapeutics Inc | Moduladores de receptores de glicocorticoides de azadecalina fundidas com octa-hidro |
| US9943505B2 (en) * | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
-
2014
- 2014-11-21 PT PT14863514T patent/PT3074011T/pt unknown
- 2014-11-21 KR KR1020167017023A patent/KR102352737B1/ko active Active
- 2014-11-21 EP EP21158231.7A patent/EP3848027B1/en active Active
- 2014-11-21 JP JP2016533614A patent/JP6516743B2/ja active Active
- 2014-11-21 WO PCT/US2014/066759 patent/WO2015077530A1/en active Application Filing
- 2014-11-21 DK DK14863514.7T patent/DK3074011T3/da active
- 2014-11-21 DK DK21158231.7T patent/DK3848027T3/da active
- 2014-11-21 ES ES14863514T patent/ES2743620T3/es active Active
- 2014-11-21 EP EP19177963.6A patent/EP3560493B1/en active Active
- 2014-11-21 CN CN201910143177.XA patent/CN109761976B/zh active Active
- 2014-11-21 EP EP14863514.7A patent/EP3074011B1/en active Active
- 2014-11-21 CN CN201480074087.5A patent/CN106029066B/zh active Active
- 2014-11-21 MX MX2016006725A patent/MX368167B/es active IP Right Grant
- 2014-11-21 FI FIEP21158231.7T patent/FI3848027T3/fi active
- 2014-11-21 BR BR112016011826-0A patent/BR112016011826B1/pt active IP Right Grant
- 2014-11-21 ES ES19177963T patent/ES2869172T3/es active Active
- 2014-11-21 MY MYPI2016000978A patent/MY180141A/en unknown
- 2014-11-21 PL PL21158231.7T patent/PL3848027T3/pl unknown
- 2014-11-21 EP EP23157691.9A patent/EP4219494A1/en active Pending
- 2014-11-21 ES ES21158231T patent/ES2943542T3/es active Active
- 2014-11-21 CA CA2931302A patent/CA2931302C/en active Active
- 2014-11-21 PL PL19177963T patent/PL3560493T3/pl unknown
- 2014-11-21 PT PT211582317T patent/PT3848027T/pt unknown
- 2014-11-21 US US14/549,885 patent/US10047082B2/en active Active
- 2014-11-21 PL PL14863514T patent/PL3074011T3/pl unknown
- 2014-11-21 AU AU2014352915A patent/AU2014352915B2/en active Active
- 2014-11-21 RU RU2016123449A patent/RU2674983C1/ru active
-
2016
- 2016-05-24 PH PH12016500968A patent/PH12016500968B1/en unknown
- 2016-05-25 IL IL245848A patent/IL245848B/en active IP Right Grant
- 2016-06-14 ZA ZA2016/04026A patent/ZA201604026B/en unknown
-
2017
- 2017-10-25 JP JP2017206081A patent/JP2018012734A/ja active Pending
-
2018
- 2018-07-16 US US16/036,001 patent/US20190135805A1/en not_active Abandoned
- 2018-10-16 US US16/161,642 patent/US10323034B2/en active Active
-
2019
- 2019-03-28 JP JP2019063279A patent/JP2019094355A/ja not_active Withdrawn
- 2019-04-12 US US16/382,474 patent/US10787449B2/en active Active
-
2020
- 2020-08-04 US US16/984,914 patent/US11370789B2/en active Active
-
2021
- 2021-01-12 US US17/146,608 patent/US11560379B2/en active Active
- 2021-02-15 JP JP2021021630A patent/JP2021073315A/ja not_active Withdrawn
-
2022
- 2022-11-28 JP JP2022189246A patent/JP2023011052A/ja not_active Withdrawn
- 2022-12-09 US US18/078,389 patent/US12139486B2/en active Active
-
2024
- 2024-08-30 JP JP2024148322A patent/JP2024170470A/ja active Pending
- 2024-10-04 US US18/906,346 patent/US20250034140A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2869172T3 (es) | Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro | |
| AR128490A2 (es) | Compuesto derivado de carboxamida para el control de endoparásitos | |
| UY35908A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| CU20180144A7 (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| ES2753816T3 (es) | Moduladores del receptor de glucocorticoides de azadecalina condensada con heteroaril-cetona | |
| CY1120188T1 (el) | ΠΑΡΑΓΩΓΑ ΝΑΦΘΥΡΙΔΙΝΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΙΝΤΕΓΚΡΙΝΗΣ αvβ6 | |
| CY1124537T1 (el) | Παραγωγο πυριδονης που εχει τετραϋδροπυρανυλ μεθυλ ομαδα | |
| AR090760A1 (es) | Compuestos de benzotiazol y su uso contra el virus de hiv | |
| AR098136A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| AR099995A1 (es) | Piridilamidinas fungicidas | |
| CU20140105A7 (es) | Composición para el control de plagas que incluye un derivado de iminopiridina novedoso | |
| CU24411B1 (es) | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos | |
| AR099677A1 (es) | Compuesto heterocíclico fusionado y su uso para el control de plagas | |
| NI201500130A (es) | 2-azabiciclo sustituidos y su uso como moduladores del receptor de orexina | |
| GT201400290A (es) | Carboxamidas heterociclicas fungicidas | |
| MX2016012719A (es) | Uso de compuesto heterociclicos para controlar nematodos. | |
| PE20160661A1 (es) | Compuesto de azapiridona y sus usos de los mismos | |
| CR20210079A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| PE20160523A1 (es) | Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis | |
| PE20180327A1 (es) | Proceso para preparar 4-amino-piridazinas | |
| CR20150061A (es) | Compuesto de pirazolopirimidinas | |
| AR105991A1 (es) | Heteroarilos sustituidos con pirazolilo y su uso como medicamentos | |
| ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a | |
| CO6150150A2 (es) | Derivados de 7-alquinil-1,8-naftiridonas su prepacion y su aplicacion en terapeutica | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida |